NeuroPace RNS System Demonstrates Long-Term Benefits in Real-World Epilepsy Study
Summary
NeuroPace published real-world data demonstrating long-term benefits of its Responsive Neurostimulation System for treating drug-resistant epilepsy. The study showed that patients treated with the RNS System experienced sustained seizure reduction over multiple years of therapy. The RNS System is the only FDA-approved closed-loop brain-responsive neurostimulator that monitors brain activity and delivers targeted stimulation to stop seizures before they start.
Why it matters
These long-term real-world data support the durability and effectiveness of closed-loop neurostimulation for epilepsy, providing evidence beyond controlled clinical trials. Drug-resistant epilepsy affects approximately one-third of the 3.4 million Americans with epilepsy, leaving them with limited treatment options. The RNS System's brain-responsive approach represents a personalized medicine paradigm that could inform development of similar closed-loop systems for other neurological conditions.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial